DUBLIN, Jan. 29, 2015 /PRNewswire/ --Research and Markets
(http://www.researchandmarkets.com/research/t7lvc3/global_prostate) has announced the addition of the "Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015" report to their offering.
Prostate cancer has emerged as a disease with one of the highest incidences and mortality rates in males across the world. This situation has created a large unmet medical demand for better therapeutics by patients suffering from prostate cancer due to modest response generated by presently available therapeutics. Hormone based therapeutics and chemotherapeutics helped in improving the patient's condition but they have side effects and modest pharmacological benefits reflecting necessity for better product. Pharmaceutical companies focused their efforts to resolve this problem by increasing research and development activities by diverging more funds in this segment. As a result, prophylactic prostate cancer vaccine was developed and introduced in market which is going to witness competition from innovative products in next few years.
Prostate cancer vaccine is a recent development which is more potent than presently available prostate cancer therapeutics in providing better medical care. Prophylactic nature of this vaccine makes it possible to prevent the future incidences of prostate cancer. Besides, it can also prevent the relapse, provides long- term immunity, decrease morbidity and mortality rates along with increasing longevity. Owing to these benefits offered by prostate cancer vaccines their acceptance is increasing among patients and physicians in recent years. It is expected that due competition and increased number of products in market will cause decrease in the price of prostate cancer vaccines in coming years.
Prostate cancer vaccine utilizes different antigens like Prostate-Specific Membrane Antigen, Prostate-Specific Antigen (PSA) and Prostatic Acid Phosphatase (PAP) in pharmacological formulations. These antigens are isolated from the prostate tumor and injected into the body to activate the immune cells. They identify these antigens as non-self and begin to search and eliminate cancerous cells from body to prevent proliferation of cancerous cells. Highly specific nature causes elimination of cancerous cells in prostate while sparing normal cells leading to minimized side effects in patients.
Prostate cancer vaccines are prophylactic in nature due to which they can prevent the future incidences of cancer. Immune cells are primed to search and eliminate the cancerous cells due to which they are able to prevent relapse. Circulating cancerous cells are also targeted responsible for secondary cancer development is checked in the body. Efficacy of cancer vaccine could be monitored by checking PSA levels which may indicate improvement in patient's condition. However, these results may vary from patient to patient but significant improvement has been observed as compared to conventional therapeutic methods. Besides pharmacological benefits, this fact also reflects towards high marketing potential of prophylactic prostate cancer vaccine.
Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015 Report Highlights:
- Introduction to Prostate Cancer Vaccine
- Mechanism of Prostate Cancer Vaccine
- Global Prostate Cancer Vaccine Clinical Trial Insight by Company, Country & Phase
- Global Prostate Cancer Vaccine Clinical Pipeline: 41 Vaccines
- Majority Prostate Cancer Vaccine in Phase-II: 10 Vaccines
- Marketed Prostate Cancer Vaccine: 1 (Provenge by Dendreon Corporation)
Key Topics Covered:
1. Introduction to Prostate Cancer Vaccine
2. Mechanism of Prostate Cancer Vaccine
3. Global Prostate Cancer Vaccine Market Dynamics
4. Global Prostate Cancer Vaccine Market Outlook
5. Global Prostate Cancer Vaccine Market Future Prospects
6. Personalized Cancer Vaccine Market Opportunities
7. Global Prostate Cancer Vaccines Clinical Trial Insight by Company, Country & Phase
8. Marketed Prostate Cancer Vaccines by Company & Country
9. Suspended & Discontinued Prostate Cancer Vaccines in Clinical Trials
10. Competitive Landscape
- Adamis Pharmaceuticals
- Aduro BioTech
- Bellicum Pharmaceuticals
- Dendreon Corporation
- Generex Biotechnology Corporation
For more information visit http://www.researchandmarkets.com/research/t7lvc3/global_prostate
Media Contact: Laura Wood , +353-1-481-1716, email@example.com
SOURCE Research and Markets